Xtant acquires of nanOss from RTI Surgical for $2M plus earnouts.

Expands Xtant’s Manufacturing Capabilities and Capacity to Drive Growth
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has acquired the nanOss production operations from RTI Surgical, Inc., a leading CDMO in regenerative medicine.
Under the terms of the purchase agreement, Xtant acquired certain assets, including equipment and inventory, used in RTI’s synthetic bone graft business, and assumed from RTI the lease for the nanOss production facility located in Gre...


Join thousands of ortho pros reading exclusive OrthoStreams articles, hot startups, early trends, market insights, and the Daily Newsletter for just $1/day.
Subscribe Now—Stay Ahead!

Scroll to Top